Trial Profile
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Muscle weakness; Myasthenia gravis
- Focus Adverse reactions; Registrational
- Acronyms ADAPT+
- Sponsors argenx
- 07 Mar 2024 According to an argenx SE media release, data from this trial, will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, CO from April 13-18, 2024.
- 27 Apr 2023 Results assessing long-term safety and efficacy presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 27 Apr 2023 Results of pooled analysis (phase 2 myasthenia gravis, phase 2 open-label in pemphigus, ADAPT, ADVANCE, and ADAPT+) assessing the safety profile of efgartigimod across different IgG-mediated disorders, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.